# The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

> **NCT04876651** · PHASE3 · TERMINATED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Ltd** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **OTHER:** 177Lu-DOTA-rosopatamb
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04876651
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-29
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Telix is conducting a separate Phase 3 clinical trial - ProstACT Global NCT06520345- to expedite the development and approval process under an IND. Consequently, this necessitates the closure of the current 177Lu-TLX591-002 Phase 3 trial.
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876651, "The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04876651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*